BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 32060633)

  • 1. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    De Nunzio C; Salonia A; Gacci M; Ficarra V
    World J Urol; 2020 Nov; 38(11):2771-2779. PubMed ID: 32060633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
    Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
    BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
    Latil A; Pétrissans MT; Rouquet J; Robert G; de la Taille A
    Prostate; 2015 Dec; 75(16):1857-67. PubMed ID: 26306400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy.
    Ficarra V; Rossanese M; Zazzara M; Giannarini G; Abbinante M; Bartoletti R; Mirone V; Scaglione F
    Curr Urol Rep; 2014 Dec; 15(12):463. PubMed ID: 25312251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serenoa repens for benign prostatic hyperplasia.
    Tacklind J; Macdonald R; Rutks I; Stanke JU; Wilt TJ
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD001423. PubMed ID: 23235581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.
    Russo A; Capogrosso P; La Croce G; Ventimiglia E; Boeri L; Briganti A; Damiano R; Montorsi F; Salonia A
    Expert Opin Drug Saf; 2016 Dec; 15(12):1661-1670. PubMed ID: 27232207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
    Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.
    MacDonald R; Tacklind JW; Rutks I; Wilt TJ
    BJU Int; 2012 Jun; 109(12):1756-61. PubMed ID: 22551330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Our experience of using hexane extract of Serenoa Repens fruit (Permixone) in the treatment of LUTS in clinical practice].
    Kuzmenko AV; Gyaurgiev TA; Kuzmenko GA
    Urologiia; 2022 May; (2):84-89. PubMed ID: 35485819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serenoa repens for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Current Evidence and Its Clinical Implications in Naturopathic Medicine.
    Ooi SL; Pak SC
    J Altern Complement Med; 2017 Aug; 23(8):599-606. PubMed ID: 28436684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials.
    Russo GI; Scandura C; Di Mauro M; Cacciamani G; Albersen M; Hatzichristodoulou G; Fode M; Capogrosso P; Cimino S; Marcelissen T; Cornu JN; Gacci M; Minervini A; Cocci A;
    Eur Urol Focus; 2021 Mar; 7(2):420-431. PubMed ID: 31952967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hexanic Extract of Serenoa repens (Permixon
    Blair HA
    Drugs Aging; 2022 Mar; 39(3):235-243. PubMed ID: 35237936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?
    Chiang BJ; Kuo HC; Liao CH
    Toxins (Basel); 2019 Sep; 11(9):. PubMed ID: 31546892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Combination Therapy with α-Blockers and Hexanic Extract of
    De Nunzio C; Salonia A; Gacci M; Ficarra V
    J Clin Med; 2022 Dec; 11(23):. PubMed ID: 36498751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
    De Nunzio C; Presicce F; Tubaro A
    Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.
    Bertaccini A; Giampaoli M; Cividini R; Gattoni GL; Sanseverino R; Realfonso T; Napodano G; Fandella A; Guidoni E; Prezioso D; Galasso R; Cicalese C; Scattoni V; Armenio A; Conti G; Corinti M; Spasciani R; Liguori G; Lampropoulou N; Martorana G
    Arch Ital Urol Androl; 2012 Sep; 84(3):117-22. PubMed ID: 23210402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do we really need herbal medicine in LUTS/BPH treatment in the 21
    Pinggera GM; Frauscher F
    Expert Opin Drug Saf; 2016 Dec; 15(12):1573-1575. PubMed ID: 27461908
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis.
    Wang X; Wang X; Li S; Meng Z; Liu T; Zhang X
    PLoS One; 2014; 9(9):e107593. PubMed ID: 25216271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serenoa repens for benign prostatic hyperplasia.
    Wilt T; Ishani A; Mac Donald R
    Cochrane Database Syst Rev; 2002; (3):CD001423. PubMed ID: 12137626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.